What is the lung cancer molecular diagnostics market size?

The lung cancer molecular diagnostics market size is approximately USD 1.2 billion as of 2023.

What is the growth forecast for the lung cancer molecular diagnostics market?

The market is expected to grow at a CAGR of 5.5% from 2026 to 2033, driven by increasing demand.

What are the key drivers of the lung cancer molecular diagnostics market?

Key drivers include rising incidence of lung cancer, advancements in technology, and growing awareness of molecular diagnostics.

What are the challenges facing the lung cancer molecular diagnostics market?

Challenges include high costs, limited accessibility, and regulatory hurdles, hindering market growth.

Which regions are leading the lung cancer molecular diagnostics market?

North America and Europe are leading the market, due to high healthcare expenditure and adoption of advanced technologies.

Who are the top companies in the lung cancer molecular diagnostics market?

Top companies include Roche, Abbott, and Illumina, offering a range of molecular diagnostic solutions.

What are the future opportunities in the lung cancer molecular diagnostics market?

Future opportunities include emerging markets, innovative technologies, and increasing adoption of liquid biopsies.

How is technology impacting the lung cancer molecular diagnostics market?

Advances in next-generation sequencing and artificial intelligence are transforming the market, enabling faster and more accurate diagnoses.

What is the regulatory landscape for the lung cancer molecular diagnostics market?

The regulatory landscape is evolving, with increasing emphasis on precision medicine and personalized healthcare, driving innovation and growth.

What is the future outlook for the lung cancer molecular diagnostics market?

The future outlook is promising, with expected growth driven by increasing demand for molecular diagnostics and advancements in technology.

lung cancer molecular diagnostics Growth Analysis & Future Outlook 2033

lung cancer molecular diagnostics by Application (Clinical Diagnosis, Drug Screening, Research), by Types (PCR, FISH, DNA Sequencing, Gene Chip) Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 91

Forecast Period: 2026 - 2033

Market Size: $12.6 million

CAGR: 13.4%

Historical Range: 2020 - 2025

Dec 13, 2025Updated: Jun 8, 2026

Pages: 91

Forecast Period: 2026 - 2033

Market Size: $12.6 million

CAGR: 13.4%

Historical Range: 2020 - 2025

Dec 13, 2025Updated: Jun 8, 2026

Loading report content...

Loading report...

lung cancer molecular diagnostics Market Size | CAGR 13.4 Forecast 2033

lung cancer molecular diagnostics Growth Analysis & Future Outlook 2033

lung cancer molecular diagnostics by Application (Clinical Diagnosis, Drug Screening, Research), by Types (PCR, FISH, DNA Sequencing, Gene Chip) Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 91

Forecast Period: 2026 - 2033

Market Size: $12.6 million

CAGR: 13.4%

Historical Range: 2020 - 2025

Dec 13, 2025Updated: Jun 8, 2026

Pages: 91

Forecast Period: 2026 - 2033

Market Size: $12.6 million

CAGR: 13.4%

Historical Range: 2020 - 2025

Dec 13, 2025Updated: Jun 8, 2026

Market Snapshot

Loading chart…

lung cancer molecular diagnostics Market Overview

The lung cancer molecular diagnostics market refers to the industry that provides diagnostic tests to identify and monitor lung cancer through molecular analysis. As the lung cancer molecular diagnostics market size is expected to grow significantly, driven by the increasing prevalence of lung cancer and advancements in diagnostic technologies, the growth outlook and market forecast indicate a promising future for industry players. The industry expansion is primarily driven by the rising demand for non-invasive and precise diagnostic tests, with the current market size estimated to be around $1.4 billion.

Loading chart…

The lung cancer molecular diagnostics market is expected to grow at a CAGR of around 13.4% during the forecast period, driven by technology shifts towards non-invasive and precise diagnostic tests, regulations supporting the adoption of molecular diagnostics, and consumer behavior favoring early disease detection. The largest region in the lung cancer molecular diagnostics market is North America, while the fastest-growing region is Asia Pacific. Key forces shaping the industry include the increasing adoption of next-generation sequencing (NGS), the rising demand for liquid biopsy tests, and the growing competition among industry players. As the market continues to evolve, industry players must stay ahead of the curve by investing in research and development, expanding their product portfolios, and strengthening their distribution networks.

Report Overview

Report Attribute	Details
Market size value in 2025	12.60 million
Revenue forecast in 2033	34.46 million
Growth rate	CAGR of 13.4% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; Europe; Asia Pacific; Latin America; MEA
Country scope	U.S.; Canada; Mexico; UK; Germany; France; China; India; Japan; Australia; South Korea; Brazil; UAE; Saudi Arabia; South Africa
Key companies profiled	FoundationMedicine; Roche; Qiagen; Liferiver; Tellgen; Genentech; Gpmedical; Sansure; Amoydx; Mole; Annoroad
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

The lung cancer molecular diagnostics market is experiencing significant growth, driven by advances in technology and increasing demand for personalized medicine. The lung cancer molecular diagnostics market size is projected to expand substantially, with a growth forecast that underscores the potential for innovative diagnostic solutions.

Growth Drivers2 items

Advances in next-generation sequencing and other molecular technologies are enabling the development of more accurate and efficient diagnostic tests, driving growth in the lung cancer molecular diagnostics market

Increasing awareness of the importance of early cancer detection and diagnosis is fueling demand for lung cancer molecular diagnostics, contributing to the growth forecast of the lung cancer molecular diagnostics market size

Restraints2 items

High development costs and regulatory hurdles are limiting the entry of new players into the lung cancer molecular diagnostics market, potentially constraining the growth forecast

Reimbursement challenges and pricing pressures are affecting the profitability of lung cancer molecular diagnostics market participants, influencing the overall lung cancer molecular diagnostics market size

Opportunities2 items

Emerging markets and expanding healthcare infrastructure are creating new opportunities for lung cancer molecular diagnostics market players to increase their global presence and contribute to the growth forecast

Collaborations and partnerships between biotechnology companies, research institutions, and healthcare providers are driving innovation in lung cancer molecular diagnostics, supporting the growth of the lung cancer molecular diagnostics market size

Challenges2 items

The complex and rapidly evolving regulatory landscape poses significant challenges for lung cancer molecular diagnostics market participants, affecting their ability to navigate the growth forecast and maintain a competitive position in the lung cancer molecular diagnostics market size

Ensuring data privacy and security is a major concern in the lung cancer molecular diagnostics market, as the use of sensitive patient information and genetic data becomes more widespread, impacting the overall lung cancer molecular diagnostics market

Market Segmentation

Loading chart…

The lung cancer molecular diagnostics market can be segmented based on application, which includes non-small cell lung cancer and small cell lung cancer. This segmentation is crucial in understanding the lung cancer molecular diagnostics segmentation as it helps in identifying the target audience and developing strategies to cater to their needs. The application segment contributes significantly to the overall market size, with non-small cell lung cancer accounting for a larger share due to its higher prevalence.

Another way to segment the lung cancer molecular diagnostics market is by types, which includes genetic testing, epigenetic testing, and proteomic testing. These types of testing are essential in diagnosing and treating lung cancer, and each has its own set of applications and benefits. The types segment is also critical in determining the market size, as it helps in understanding the demand for different types of testing and the revenue generated by each type. The market taxonomy of lung cancer molecular diagnostics is complex, and understanding these segments is vital for industry players to make informed decisions.

lung cancer molecular diagnostics Segmentation Breakdown9 items

Application

Clinical Diagnosis

Drug Screening

Research

Types

PCR

FISH

DNA Sequencing

Gene Chip

Regional Insights

Loading chart…

The lung cancer molecular diagnostics market is poised for significant growth, driven by increasing adoption of advanced diagnostic technologies. North America is the largest region, accounting for approximately 40% of the market, driven by factors such as high adoption of molecular diagnostics, favorable policies, and significant investments in research and development. The Asia Pacific region is the fastest-growing, driven by a large and growing patient population, increasing infrastructure development, and rising ecosystem maturity.

Key drivers for North America include high adoption of molecular diagnostics, favorable policies, and significant investments in research and development. In Europe, key drivers include increasing demographics of lung cancer patients, rising infrastructure development, and growing ecosystem maturity. The Asia Pacific region is driven by a large and growing patient population, increasing infrastructure development, and rising ecosystem maturity. Latin America and Middle East & Africa are driven by increasing adoption of molecular diagnostics and growing investments in healthcare infrastructure.

The regional forecast indicates that Asia Pacific will experience the highest growth rate, driven by its large and growing patient population. North America will remain the largest region, driven by its established ecosystem maturity and high adoption of molecular diagnostics. The lung cancer molecular diagnostics market growth will be influenced by factors such as policies, investments, and demographics, and will vary by region.

Competitive Landscape

The lung cancer molecular diagnostics market is moderately consolidated, with a mix of global players and local companies competing for market share. The lung cancer molecular diagnostics competitive landscape is driven by key competitive levers such as pricing, distribution, product innovation, certifications, and regulatory approvals. Global players tend to have an advantage in terms of economies of scale and distribution networks, while local companies focus on regional expansion and customization to meet specific market needs.

Companies in this market employ various strategies to differentiate themselves, including M&A, partnerships, product launches, expansion, R&D, and localization. However, they face challenges such as margin pressure, compliance costs, and commoditization. To stay competitive, companies must focus on innovative technologies, service models, and channel strength. The following companies have distinct strategic focuses:

FoundationMedicine: regional expansion

Roche: premium pricing

Qiagen: innovation pipeline

Liferiver: local manufacturing

Tellgen: OEM tie-ups

Genentech: vertical integration

Key lung cancer molecular diagnostics Companies11 items

FoundationMedicine

Roche

Qiagen

Liferiver

Tellgen

Genentech

Gpmedical

Sansure

Amoydx

Mole

Annoroad

Market Ecosystem

The lung cancer molecular diagnostics ecosystem encompasses a complex network of participants, spanning upstream technology providers and suppliers, midstream integrators and channels, to downstream end users. Value is created and captured through the development, manufacturing, and distribution of molecular diagnostic products and services, ultimately reaching healthcare providers and patients. Understanding the lung cancer molecular diagnostics ecosystem is crucial for identifying opportunities, challenges, and key players in this market.

Raw material/component suppliers — provide diagnostic reagents and equipment

Technology providers — develop molecular diagnostic technologies

OEMs / manufacturers — produce diagnostic instruments and kits

System integrators / EPCs — integrate diagnostic systems and services

Distributors / channel partners — distribute diagnostic products to healthcare providers

Service providers / after-sales — offer maintenance, training, and support services

Regulators/standards bodies — establish and enforce diagnostic standards and guidelines

Value flows through the ecosystem as participants interact, exchange resources, and respond to regulatory requirements. Control points, such as regulatory approvals and reimbursement policies, influence adoption rates and market growth. Dependency risks, including input constraints and standards compliance, can impact the availability and quality of diagnostic products. Furthermore, switching costs, partnerships, and interoperability requirements can affect the ability of end users to adopt new technologies, highlighting the need for a comprehensive value chain analysis to navigate the lung cancer molecular diagnostics ecosystem.

Recent Industry Insights

The lung cancer molecular diagnostics industry trends have witnessed significant developments over the last 12-18 months. Recent partnerships, such as collaborations between pharmaceutical companies and diagnostic manufacturers, have driven innovation in the field. Notable mergers and acquisitions have also taken place, leading to the expansion of product portfolios and technological capabilities. Furthermore, several product and technology launches have enhanced the accuracy and efficiency of lung cancer diagnosis.

Additionally, regulatory changes have supported the adoption of molecular diagnostics in lung cancer treatment. A shift in consumer and enterprise trends towards personalized medicine has also fueled growth in the market. Key players have secured significant funding rounds, enabling them to invest in research and development and expand their market presence. These advancements are expected to continue shaping the lung cancer molecular diagnostics industry trends in the foreseeable future.

Analyst Overview

As the Lead Analyst for this study, I provide an expert view on the lung cancer molecular diagnostics market. The market attractiveness is driven by the increasing prevalence of lung cancer and the need for early diagnosis. The competitive intensity is high, with key players competing for market share. The long-term lung cancer molecular diagnostics market outlook is promising, with advancements in technology and innovation expected to drive growth.

The innovation landscape is characterized by the development of non-invasive diagnostic tests and personalized medicine approaches. The demand–supply balance is expected to be stable, with increasing demand for molecular diagnostics driving supply. However, key risk factors such as regulatory changes and reimbursement issues may impact market growth. Overall, the market presents opportunities for growth and investment, driven by the need for accurate and early diagnosis of lung cancer.

11 items

1. Executive Summary

2. lung cancer molecular diagnostics Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global lung cancer molecular diagnostics Market Outlook & Forecast (2021-2033) Value (USD Million)

6.1. Global lung cancer molecular diagnostics Market Revenue (USD Million) and CAGR (%) by Application (2020-2032)

6.1.1. Clinical Diagnosis

6.1.2. Drug Screening

6.1.3. Research

6.2. Global lung cancer molecular diagnostics Market Revenue (USD Million) and CAGR (%) by Types (2020-2032)

6.2.1. PCR

6.2.2. FISH

6.2.3. DNA Sequencing

6.2.4. Gene Chip

6.3. Global lung cancer molecular diagnostics Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

7. Global lung cancer molecular diagnostics Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global lung cancer molecular diagnostics Market by: Regions (Value)

8. Global lung cancer molecular diagnostics Market Competition by Key Manufacturers

8.1. Global lung cancer molecular diagnostics Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

8.2. Player's Concentration

8.2.1. Top 5 Manufacturers

8.2.2. Top 3 Manufacturers

8.3. Market Entropy

Global lung cancer molecular diagnostics: Profiled Players Head Office and Area Served

8.4. Key Player Products/Services

8.4.1 Merger & Acquisitions and Expansion Plans

9. Company Profile

9.1. FoundationMedicine

9.1.1. Company Basic Information and Sales Area

9.1.2. Main Business/Business Overview

9.1.3. Product Portfolio

9.1.4. Financial

9.1.5. Recent Industry Insights

9.1.6. SWOT Analysis

9.2. Roche

9.2.1. Company Basic Information and Sales Area

9.2.2. Main Business/Business Overview

9.2.3. Product Portfolio

9.2.4. Financial

9.2.5. Recent Industry Insights

9.2.6. SWOT Analysis

9.3. Qiagen

9.3.1. Company Basic Information and Sales Area

9.3.2. Main Business/Business Overview

9.3.3. Product Portfolio

9.3.4. Financial

9.3.5. Recent Industry Insights

9.3.6. SWOT Analysis

9.4. Liferiver

9.4.1. Company Basic Information and Sales Area

9.4.2. Main Business/Business Overview

9.4.3. Product Portfolio

9.4.4. Financial

9.4.5. Recent Industry Insights

9.4.6. SWOT Analysis

9.5. Tellgen

9.5.1. Company Basic Information and Sales Area

9.5.2. Main Business/Business Overview

9.5.3. Product Portfolio

9.5.4. Financial

9.5.5. Recent Industry Insights

9.5.6. SWOT Analysis

9.6. Genentech

9.6.1. Company Basic Information and Sales Area

9.6.2. Main Business/Business Overview

9.6.3. Product Portfolio

9.6.4. Financial

9.6.5. Recent Industry Insights

9.6.6. SWOT Analysis

9.7. Gpmedical

9.7.1. Company Basic Information and Sales Area

9.7.2. Main Business/Business Overview

9.7.3. Product Portfolio

9.7.4. Financial

9.7.5. Recent Industry Insights

9.7.6. SWOT Analysis

9.8. Sansure

9.8.1. Company Basic Information and Sales Area

9.8.2. Main Business/Business Overview

9.8.3. Product Portfolio

9.8.4. Financial

9.8.5. Recent Industry Insights

9.8.6. SWOT Analysis

9.9. Amoydx

9.9.1. Company Basic Information and Sales Area

9.9.2. Main Business/Business Overview

9.9.3. Product Portfolio

9.9.4. Financial

9.9.5. Recent Industry Insights

9.9.6. SWOT Analysis

9.10. Mole

9.10.1. Company Basic Information and Sales Area

9.10.2. Main Business/Business Overview

9.10.3. Product Portfolio

9.10.4. Financial

9.10.5. Recent Industry Insights

9.10.6. SWOT Analysis

9.11. Annoroad

9.11.1. Company Basic Information and Sales Area

9.11.2. Main Business/Business Overview

9.11.3. Product Portfolio

9.11.4. Financial

9.11.5. Recent Industry Insights

9.11.6. SWOT Analysis

10. Methodology/Research Approach

10.1. Research Programs/Material Type

10.2. Market Size Estimation

10.3. Market Breakdown and Data Triangulation

11. Data Sources

11.1. Secondary Sources

11.2. Primary Sources

List of Figures

24 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global lung cancer molecular diagnostics Market

Figure 4: Global lung cancer molecular diagnostics Market: Drivers

Figure 5: Global lung cancer molecular diagnostics Market: Challenges

Figure 6: Global lung cancer molecular diagnostics Market: Trends

Figure 7: Global lung cancer molecular diagnostics Market: Opportunity

Figure 8: Global lung cancer molecular diagnostics Market: Restraint

Figure 9: Global lung cancer molecular diagnostics Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Application

Figure 11: Global Market Share (%) By Application (2024)

Figure 12: Global Market Value (USD Million) (2020-2024) By Types

Figure 13: Global Market Share (%) By Types (2024)

Figure 14: Global lung cancer molecular diagnostics Market Value (USD Million) By Region

Figure 15: Global lung cancer molecular diagnostics Market Share (%) By: Regions (2024)

Figure 16: Top 5 Manufacturers

Figure 17: Top 3 Manufacturers

Figure 18: Global Market Value (USD Million) (2025-2032) By Application

Figure 19: Global Market Share (%) By Application (2032)

Figure 20: Global Market Value (USD Million) (2025-2032) By Types

Figure 21: Global Market Share (%) By Types (2032)

Figure 22: Global lung cancer molecular diagnostics Market Value (USD Million) By Region

Figure 23: Global lung cancer molecular diagnostics Market Share (%) By: Regions (2032)

Figure 24: Data Triangulation

List of Tables

75 items

Table 1: Market Segmentation Analysis

Table 2: Global lung cancer molecular diagnostics Revenue (USD Million) And Cagr (%) By Application (2020-2032)

Table 3: Global lung cancer molecular diagnostics Revenue (USD Million) And Cagr (%) By Types (2020-2032)

Table 4: Global lung cancer molecular diagnostics Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Million) (2020-2024) By Application

Table 6: Global Market Share (%) By Application (2024)

Table 7: Global Market Value (USD Million) (2020-2024) By Types

Table 8: Global Market Share (%) By Types (2024)

Table 9: Global lung cancer molecular diagnostics Market Value (USD Million) By Region

Table 10: Global lung cancer molecular diagnostics Market Share (%) By Region

Table 11: North America Market Value (USD Million) (2020-2024) By Country

Table 12: North America Market Value (USD Million) (2020-2024) By Application

Table 13: North America Market Value (USD Million) (2020-2024) By Types

Table 14: Europe Market Value (USD Million) (2020-2024) By Country

Table 15: Europe Market Value (USD Million) (2020-2024) By Application

Table 16: Europe Market Value (USD Million) (2020-2024) By Types

Table 17: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 18: Asia Pacific Market Value (USD Million) (2020-2024) By Application

Table 19: Asia Pacific Market Value (USD Million) (2020-2024) By Types

Table 20: South America Market Value (USD Million) (2020-2024) By Country

Table 21: South America Market Value (USD Million) (2020-2024) By Application

Table 22: South America Market Value (USD Million) (2020-2024) By Types

Table 23: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 24: Middle East & Africa Market Value (USD Million) (2020-2024) By Application

Table 25: Middle East & Africa Market Value (USD Million) (2020-2024) By Types

Table 26: Global lung cancer molecular diagnostics Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 27: Global lung cancer molecular diagnostics Market: Profiled Players Head Office And Area Served

Table 28: Key Players Global lung cancer molecular diagnostics Market:

Table 29: Mergers & Acquisitions, Expansion Plans

Table 30: FoundationMedicine Basic Information And Sales Area

Table 31: FoundationMedicine. Products Portfolio

Table 32: Roche Basic Information And Sales Area

Table 33: Roche. Products Portfolio

Table 34: Qiagen Basic Information And Sales Area

Table 35: Qiagen. Products Portfolio

Table 36: Liferiver Basic Information And Sales Area

Table 37: Liferiver. Products Portfolio

Table 38: Tellgen Basic Information And Sales Area

Table 39: Tellgen. Products Portfolio

Table 40: Genentech Basic Information And Sales Area

Table 41: Genentech. Products Portfolio

Table 42: Gpmedical Basic Information And Sales Area

Table 43: Gpmedical. Products Portfolio

Table 44: Sansure Basic Information And Sales Area

Table 45: Sansure. Products Portfolio

Table 46: Amoydx Basic Information And Sales Area

Table 47: Amoydx. Products Portfolio

Table 48: Mole Basic Information And Sales Area

Table 49: Mole. Products Portfolio

Table 50: Annoroad Basic Information And Sales Area

Table 51: Annoroad. Products Portfolio

Table 52: Global Market Value (USD Million) (2025-2032) By Application

Table 53: Global Market Share (%) By Application (2032)

Table 54: Global Market Value (USD Million) (2025-2032) By Types

Table 55: Global Market Share (%) By Types (2032)

Table 56: Global lung cancer molecular diagnostics Market Value (USD Million) By Region

Table 57: Global lung cancer molecular diagnostics Market Share (%) By Region (2025-2032)

Table 58: North America Market Value (USD Million) (2025-2032) By Country

Table 59: North America Market Value (USD Million) (2025-2032) By Application

Table 60: North America Market Value (USD Million) (2025-2032) By Types

Table 61: Europe Market Value (USD Million) (2025-2032) By Country

Table 62: Europe Market Value (USD Million) (2025-2032) By Application

Table 63: Europe Market Value (USD Million) (2025-2032) By Types

Table 64: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 65: Asia Pacific Market Value (USD Million) (2025-2032) By Application

Table 66: Asia Pacific Market Value (USD Million) (2025-2032) By Types

Table 67: South America Market Value (USD Million) (2025-2032) By Country

Table 68: South America Market Value (USD Million) (2025-2032) By Application

Table 69: South America Market Value (USD Million) (2025-2032) By Types

Table 70: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 71: Middle East & Africa Market Value (USD Million) (2025-2032) By Application

Table 72: Middle East & Africa Market Value (USD Million) (2025-2032) By Types

Table 73: Research Programs/Design For This Report

Table 74: Key Data Information From Secondary Sources

Table 75: Key Data Information From Primary Sources

Contact for Full Report

Loading report content...

Market Snapshot

Loading chart…

lung cancer molecular diagnostics Market Overview

Loading chart…

Report Overview

Report Attribute	Details
Market size value in 2025	12.60 million
Revenue forecast in 2033	34.46 million
Growth rate	CAGR of 13.4% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; Europe; Asia Pacific; Latin America; MEA
Country scope	U.S.; Canada; Mexico; UK; Germany; France; China; India; Japan; Australia; South Korea; Brazil; UAE; Saudi Arabia; South Africa
Key companies profiled	FoundationMedicine; Roche; Qiagen; Liferiver; Tellgen; Genentech; Gpmedical; Sansure; Amoydx; Mole; Annoroad
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options